Selected research
Industry Research
Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Research Report 2026
Market perspective
The global Phosphoinositide 3-Kinase (PI3K) Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Phosphoinositide 3-Kinase (PI3K) Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Phosphoinositide 3-Kinase (PI3K) Inhibitors market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Phosphoinositide 3-Kinase (PI3K) Inhibitors market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Phosphoinositide 3-Kinase (PI3K) Inhibitors include Novartis AG, Bayer AG, Verastem Inc., TG Therapeutics Inc. and Gilead Sciences Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Phosphoinositide 3-Kinase (PI3K) Inhibitors market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Phosphoinositide 3-Kinase (PI3K) Inhibitors.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Company
Novartis AG
Bayer AG
Verastem Inc.
TG Therapeutics Inc.
Gilead Sciences Inc.
Phosphoinositide 3-Kinase (PI3K) Inhibitors Segment by Type
CLL - Chronic Iymphocytic Ieukemia
FL - Follicular Iymphoma
Other Indications
Phosphoinositide 3-Kinase (PI3K) Inhibitors Segment by Application
Clinic
hospital
Research Institutes and Research Institutions
Other
Phosphoinositide 3-Kinase (PI3K) Inhibitors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphoinositide 3-Kinase (PI3K) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Phosphoinositide 3-Kinase (PI3K) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphoinositide 3-Kinase (PI3K) Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Phosphoinositide 3-Kinase (PI3K) Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CLL - Chronic Iymphocytic Ieukemia
- FL - Follicular Iymphoma
- Other Indications
Applications
- Clinic
- hospital
- Research Institutes and Research Institutions
- Other
Companies covered
- Novartis AG
- Bayer AG
- Verastem Inc.
- TG Therapeutics Inc.
- Gilead Sciences Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Phosphoinositide 3-Kinase (PI3K) Inhibitors by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CLL - Chronic Iymphocytic Ieukemia
- 2.2.3 FL - Follicular Iymphoma
- 2.2.4 Other Indications
- 2.3 Phosphoinositide 3-Kinase (PI3K) Inhibitors by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinic
- 2.3.3 hospital
- 2.3.4 Research Institutes and Research Institutions
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Phosphoinositide 3-Kinase (PI3K) Inhibitors Breakdown Data by Type
- 3.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historic Market Size by Type (2021-2026)
- 3.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Forecasted Market Size by Type (2027-2032)
4 Phosphoinositide 3-Kinase (PI3K) Inhibitors Breakdown Data by Application
- 4.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historic Market Size by Application (2021-2026)
- 4.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Perspective (2021-2032)
- 5.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Growth Trends by Region
- 5.2.1 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Phosphoinositide 3-Kinase (PI3K) Inhibitors Historic Market Size by Region (2021-2026)
- 5.2.3 Phosphoinositide 3-Kinase (PI3K) Inhibitors Forecasted Market Size by Region (2027-2032)
- 5.3 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Dynamics
- 5.3.1 Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Trends
- 5.3.2 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Drivers
- 5.3.3 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Challenges
- 5.3.4 Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Phosphoinositide 3-Kinase (PI3K) Inhibitors Players by Revenue
- 6.1.1 Global Top Phosphoinositide 3-Kinase (PI3K) Inhibitors Players by Revenue (2021-2026)
- 6.1.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Revenue Market Share by Players (2021-2026)
- 6.2 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Phosphoinositide 3-Kinase (PI3K) Inhibitors Head Office and Area Served
- 6.4 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Players, Product Type & Application
- 6.5 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Manufacturers Established Date
- 6.6 Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size (2021-2032)
- 7.2 North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2021-2026)
- 7.4 North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size (2021-2032)
- 8.2 Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2021-2026)
- 8.4 Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size (2021-2032)
- 9.2 Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size (2021-2032)
- 10.2 South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2021-2026)
- 10.4 South America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size (2021-2032)
- 11.2 Middle East & Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis AG
- 12.1.1 Novartis AG Company Information
- 12.1.2 Novartis AG Business Overview
- 12.1.3 Novartis AG Revenue in Phosphoinositide 3-Kinase (PI3K) Inhibitors Business (2021-2026)
- 12.1.4 Novartis AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
- 12.1.5 Novartis AG Recent Developments
- 12.2 Bayer AG
- 12.2.1 Bayer AG Company Information
- 12.2.2 Bayer AG Business Overview
- 12.2.3 Bayer AG Revenue in Phosphoinositide 3-Kinase (PI3K) Inhibitors Business (2021-2026)
- 12.2.4 Bayer AG Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
- 12.2.5 Bayer AG Recent Developments
- 12.3 Verastem Inc.
- 12.3.1 Verastem Inc. Company Information
- 12.3.2 Verastem Inc. Business Overview
- 12.3.3 Verastem Inc. Revenue in Phosphoinositide 3-Kinase (PI3K) Inhibitors Business (2021-2026)
- 12.3.4 Verastem Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
- 12.3.5 Verastem Inc. Recent Developments
- 12.4 TG Therapeutics Inc.
- 12.4.1 TG Therapeutics Inc. Company Information
- 12.4.2 TG Therapeutics Inc. Business Overview
- 12.4.3 TG Therapeutics Inc. Revenue in Phosphoinositide 3-Kinase (PI3K) Inhibitors Business (2021-2026)
- 12.4.4 TG Therapeutics Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
- 12.4.5 TG Therapeutics Inc. Recent Developments
- 12.5 Gilead Sciences Inc.
- 12.5.1 Gilead Sciences Inc. Company Information
- 12.5.2 Gilead Sciences Inc. Business Overview
- 12.5.3 Gilead Sciences Inc. Revenue in Phosphoinositide 3-Kinase (PI3K) Inhibitors Business (2021-2026)
- 12.5.4 Gilead Sciences Inc. Phosphoinositide 3-Kinase (PI3K) Inhibitors Product Portfolio
- 12.5.5 Gilead Sciences Inc. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst